• Dong-A Pharmaceutical subsidiary Dong-A ST received South Korean regulatory approval for gastritis treatment Stillen Q on Oct. 30, 2026.
• The treatment reduces dosing to once daily, compared with three times daily for Stillen and twice daily for Stillen 2X.
• A domestic launch remains subject to a review of market conditions and commercial viability.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dong-A Pharmaceutical Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261102800007), on November 02, 2026, and is solely responsible for the information contained therein.